A practical synthesis for the key intermediate of apixaban

被引:4
作者
Dong, Wenwen [1 ]
Gong, Tengfei [1 ]
Liu, Chaoyang [1 ]
Lin, Jia [1 ]
Jia, Qiang [2 ]
Chu, Changhu [1 ]
机构
[1] East China Univ Sci & Technol, Engn Res Ctr Pharmaceut Proc Chem, Sch Pharm, Shanghai Key Lab New Drug Design,Minist Educ, 130 Meilong Rd, Shanghai 200237, Peoples R China
[2] Seasons Biotechnol Taizhou Co Ltd, 21 Jiutiao Rd, Taizhou 318000, Zhejiang, Peoples R China
来源
MONATSHEFTE FUR CHEMIE | 2024年 / 155卷 / 01期
基金
中国国家自然科学基金;
关键词
Apixaban intermediate; Synthesis; Amine oxidation; Sodium chlorite; ORALLY BIOAVAILABLE INHIBITOR; FACTOR XA INHIBITOR; HIGHLY POTENT; BMS-562247; DISCOVERY; SAFETY;
D O I
10.1007/s00706-023-03143-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Apixaban is a highly potent, selective, and efficacious inhibitor of blood coagulation factor Xa. A practical and efficient process has been developed for the preparation of the key intermediate of apixaban. Starting from inexpensive 4-chloronitrobenzene and piperidine, an eight-step procedure for the intermediate has been developed. In this case, sodium chlorite is used twice to oxidize the piperidine cycle to the corresponding lactam under a CO2 atmosphere, resulting in the construction of two lactams. Furthermore, most of these reactions are highly efficient and practical as they occur under mild conditions. Most of the intermediates can be obtained through simple slurry or recrystallization, and column chromatography purification is not necessary.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 21 条
  • [1] Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa
    Bauer, K. A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 12 - 19
  • [2] Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
    Bauersachs, Rupert
    Berkowitz, Scott D.
    Brenner, Benjamin
    Buller, Harry R.
    Decousus, Herve
    Gallus, Alex S.
    Lensing, Anthonie W.
    Misselwitz, Frank
    Prins, Martin H.
    Raskob, Gary E.
    Segers, Annelise
    Verhamme, Peter
    Wells, Phil
    Agnelli, Giancarlo
    Bounameaux, Henri
    Cohen, Alexander
    Davidson, Bruce L.
    Piovella, Franco
    Schellong, Sebastian
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) : 2499 - 2510
  • [3] A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions
    Brown, Dean G.
    Wobst, Heike J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (05) : 2312 - 2338
  • [4] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    Buller, H.
    Deitchman, D.
    Prins, M.
    Segers, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) : 1313 - 1318
  • [5] Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
    Byon, Wonkyung
    Garonzik, Samira
    Boyd, Rebecca A.
    Frost, Charles E.
    [J]. CLINICAL PHARMACOKINETICS, 2019, 58 (10) : 1265 - 1279
  • [6] Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
    Frost, Charles
    Nepal, Sunil
    Wang, Jessie
    Schuster, Alan
    Byon, Wonkyung
    Boyd, Rebecca A.
    Yu, Zhigang
    Shenker, Andrew
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    LaCreta, Frank
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (05) : 776 - 786
  • [7] Ji Y, 2011, CHEM ABSTR, V154
  • [8] Ji Y, 2011, Chinese patent, Patent No. 101967145
  • [9] ALTERNATE SYNTHESIS OF APIXABAN (BMS-562247), AN INHIBITOR OF BLOOD COAGULATION FACTOR XA
    Jiang, Jian'an
    Ji, Yafei
    [J]. SYNTHETIC COMMUNICATIONS, 2013, 43 (01) : 72 - 79
  • [10] Apixaban: an Oral Direct Factor-Xa Inhibitor
    Jimenez, David
    Yusen, Roger D.
    Ramacciotti, Eduardo
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 187 - 201